FDA Brief

Warning letters Drugs

FDA warning letter to

LiquidCapsule Manufacturing, LLC

High riskIssued Dec 19, 2025Posted Jan 6Center for Drug Evaluation and Research (CDER)

LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

What happened

FDA inspected LiquidCapsule Manufacturing's drug manufacturing facility in Tampa, Florida, from June 25 to July 3, 2025. The agency found significant CGMP violations, including inadequate identity testing of incoming components (one high-risk component with a hazardous impurity), a drug-strength test not shown equivalent to the USP (United States Pharmacopeia) method, an inadequate stability program, incomplete batch records, and inadequate process and (b)(4) system validation. FDA also cited similar CGMP observations from a February 5 to 9, 2024, inspection.

What FDA found

  1. The firm did not adequately test each incoming component lot for identity and did not establish the reliability of supplier Certificates of Analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm lacked scientifically sound laboratory controls and did not show its drug-strength test method was equivalent to the USP method or qualify its third-party labs.

    21 CFR 211.160(b)
  3. The firm did not have an adequate stability program to show drug products meet specifications through their labeled shelf life.

    21 CFR 211.166(a)
  4. The firm's batch records were incomplete, with missing in-process results and pre-filled initials and dates.

    21 CFR 211.188
  5. The firm did not adequately validate its manufacturing process, including filling and packaging, or its (b)(4) system, and did not test or monitor that system for Burkholderia cepacia complex.

    21 CFR 211.100(a)
  6. FDA cited similar CGMP observations in a February 2024 inspection, showing repeated failures and inadequate quality-system oversight.

What FDA wants

FDA tells the company to correct the violations and respond in writing within 15 working days, specifying what it has done and how it will prevent recurrence. If it cannot complete corrections in that time, it must state why and provide a completion schedule; FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • brands that buy finished OTC drugs made by this facility
  • drugmakers that rely on supplier Certificates of Analysis or third-party test labs
  • quality teams using (b)(4) systems or monitoring for Burkholderia cepacia

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk